Pfizer confirms $99bn AstraZeneca bid, continues courtship
This article was originally published in Scrip
Executive Summary
AstraZeneca's share price opened up 12.6% on 28 April after Pfizer confirmed that it had made a £58.7bn ($99bn) takeover bid for the UK firm. Pfizer is still keen to consummate a cash and shares merger, which would yield tax benefits, opportunities to cut costs, and a shared pipeline with new possibilities to develop combination products, for example in immuno-oncology.
You may also be interested in...
Gaming Whiz Brings AI Smarts To Drug Discovery
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
The Top 10 Best-Selling Drugs of 2019
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Interview: Why Biotech Companies Should Be Confident About Deals Despite Coronavirus
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
Need a specific report? 1000+ reports available
Buy Reports